[Retracted] miR‑29a inhibits human retinoblastoma progression by targeting STAT3.
- 1Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China.
- 2Department of Tumor and Hematology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China.
- 3Department of Electrical Diagnosis, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China.
Abstract
Following the publication of this paper, and a corrigendum (doi: 10.3892/or.2017.6144) published in 2021 to take account of duplicated western blot data that were identified in Fig. 4D, it has subsequently come to light that flow cytometric plots featured in Fig. 2D and Transwell invasion assay data in Fig. 3B, both on p. 742, contained data that were strikingly similar to data that had already been published in articles written by different research groups at different research institutes in a number of different journals. Given that the contentious data named above had already been published prior to the receipt of this paper at Oncology Reports, the Editor has decided that this paper should now be retracted from the Journal. After contacting the authors, they accepted the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 39: 739‑746, 2018; DOI: 10.3892/or.2017.6144].
Related
- Targeting the non-enzymatic function of DPP4 via a nanobody inhibits cerebral cavernous malformation progression.
- Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis
- Inhibition of TOP2A by columbianadin impedes malignant progression in retinoblastoma
- Statement of Retraction: Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
- PFN1 inhibits lytic replication of Kaposi sarcoma-associated herpesvirus through SQSTM1/p62-mediated selective autophagy targeting the KSHV helicase
BibTeX
@article{liu2026retracted,
title = {{[Retracted] miR‑29a inhibits human retinoblastoma progression by targeting STAT3.}},
author = {Shu Liu and Xiaomeng Zhang and Chunmei Hu and Yingxue Wang and Chunling Xu},
journal = {Oncology reports},
year = {2026},
month = oct,
doi = {10.3892/or.2026.9207},
url = {https://europepmc.org/article/MED/42852634},
note = {CC BY},
}
RIS
TY - JOUR
TI - [Retracted] miR‑29a inhibits human retinoblastoma progression by targeting STAT3.
AU - Shu Liu
AU - Xiaomeng Zhang
AU - Chunmei Hu
AU - Yingxue Wang
AU - Chunling Xu
PY - 2026
DA - 2026/10/09
JO - Oncology reports
DO - 10.3892/or.2026.9207
UR - https://europepmc.org/article/MED/42852634
AB - Following the publication of this paper, and a corrigendum (doi: 10.3892/or.2017.6144) published in 2021 to take account of duplicated western blot data that were identified in Fig. 4D, it has subsequently come to light that flow cytometric plots featured in Fig. 2D and Transwell invasion assay data in Fig. 3B, both on p. 742, contained data that were strikingly similar to data that had already been published in articles written by different research groups at different research institutes in a number of different journals. Given that the contentious data named above had already been published prior to the receipt of this paper at Oncology Reports, the Editor has decided that this paper should now be retracted from the Journal. After contacting the authors, they accepted the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 39: 739‑746, 2018; DOI: 10.3892/or.2017.6144].
SN - 1021-335X
SN - 1791-2431
ER -